Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025. The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation. Details of the abstracts are listed below: Revolution Medicines Oral Presentations: Title:Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a Phase 1 study in advanced solid tumorsPresenter:Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer CenterAbstract Number:CT019Session:New Frontiers in Precision OncologyDate/Time:April 27; 5:00 p.m. – 5:15 p.m. CST Title:Discovery of RMC-5127, an oral, RAS(ON) G12V-selective, noncovalent, tri-complex inhibitorPresenter:Anne Edwards, Ph.D.Abstract Number:ND06Session:New Drugs on the Horizon: Part 2Date/Time:April 27; 3:25 p.m. – 3:40 p.m. CST Revolution Medicines Poster Presentations: Title:Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)Presenter:Jia Luo, M.D., Dana-Farber Cancer InstituteAbstract Number:LB218Session:Late-Breaking Research: Clinical Research 1Date/Time:April 28; 2:00 p.m. – 5:00 p.m. CST Title:Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapiesPresenter:Mallika Singh, Ph.D.Abstract Number:LB281Session:Late-Breaking Research: Experimental and Molecular Therapeutics 3Date/Time:April 29; 9:00 a.m. – 12:00 p.m. CST Title:Combination of RAS(ON) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapyPresenter:Mariela Moreno Ayala, Ph.D.Abstract Number:6046Session:Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor ImmunityDate/Time:April 29; 2:00 p.m. – 5:00 p.m. CST Collaborator Presentations Title:Distinct regulation of Cyclin D mediates heterogenous response to RAS inhibition in colorectal cancer modelsPresenter:Philip Choi, M.D., Ph.D., Memorial Sloan Kettering Cancer CenterAbstract Number:LB293Session:Late-Breaking Research: Experimental and Molecular Therapeutics 3Date/Time:April 29; 9:00 a.m. – 12:00 p.m. CST Title:Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven by KRAS G12C amplification or NRAS G13R mutationPresenter:Hitendra Singh Solanki, Ph.D., Moffitt Cancer CenterAbstract Number:5512Session:Drug Resistance in Molecular Targeted Therapies 3Date/Time:April 29; 2:00 p.m. – 5:00 p.m. CST Title:A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in preclinical models of PDACPresenter:Caroline Broderick, Ph.D., Memorial Sloan Kettering Cancer CenterAbstract Number:5336Session:CDK InhibitorsDate/Time:April 29; 2:00 p.m. – 5:00 p.m. CST Title:Preclinical evaluation of RMC-7977, a multi-selective RAS(ON) inhibitor, as a therapeutic strategy for KRAS-mutant cholangiocarcinomaPresenter:Jingjing Jiang, Ph.D.Abstract Number:5691Session:Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2Date/Time:April 29; 2:00 p.m. – 5:00 p.m. CST Title:Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancerPresenter:Joshua H. Choe, Dana-Farber Cancer InstituteAbstract Number:5507Session:Drug Resistance in Molecular Targeted Therapies 3Date/Time:April 29; 2:00 p.m. – 5:00 p.m. CST Title:T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDACPresenter:Margo I. Orlen, Penn MedicineAbstract Number:6405Session:Checkpoints and Modulators of Tumor MicroenvironmentDate/Time:April 29; 3:25 p.m. – 3:40 p.m. CST About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn. Revolution Medicines Media & Investor Contact: [email protected] [email protected] Footer Nav Media Investors Publications Contact Careers 700 Saginaw Drive Redwood City, CA 94063 © 2026 Revolution Medicines, Inc. Legal Nav CCPA Notice Privacy Policy var s_CCSWebHostingAccount = "trcgrevmed"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/11576","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb88216\/themes\/site\/client_site_202"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNUUFuAzEI_FC0rvIhhG2auGtDBKRpfl_irdRu1UqRDwY8MJ6h9EbsYM0Jji_HJO-kN43MDtwUkLHfvRVLu2zBKpmg45XL-QngRaVOWEajiWhF2PYlF-kZdRbLSrW5KFT0OLmTpe9weVVhJ95mDtSVfCIhdylrmvTmoOiNT8EQA8-o_hTcYJL8gx2EDEpFxgj-aBD-OfvavY34OqZ9Ol8veNqUPoIF3_ADsFYoHc0AO6nbH7gypcaK7lxCCjNtFt0oz62xhNG0-f6rtnzdBwt5NNLD6k8Y4cUI","theme":"client_site_202","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"accessible_accordions":true,"chairtextvars":{"chairpersontext":"Committee Chair","chairtext":"Chair"},"lfg_accordions":{"no_functionality":1,"speed":"fast","show_text":"Show All","hide_text":"Hide All","show_all":0},"lfg_chosen":{"enabled":1,"blank_text":"Choose from list","disable_search":1,"disable_search_threshold":10},"user":{"uid":0,"permissionsHash":"95770fd847ea34edbecf4bb0c68ce0a28bab935b573dfffca78a07355e42d225"}}

The release as fetched from its publisher. revmed.com ↗